News for Glaukos Corporation (GKOS)

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal

Reassessing Glaukos Corporation: Shares are down 30%, strong Q1 results, promising pipeline, solid cash reserves, and no debt. Click for my GKOS stock update.

Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund returned 2.54% (Institutional Shares) in the quarter compared to a 3.87% gain for the Russell 3000 Health Care Index (benchmark) and a 4.72% decline for the Russell […]

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

On May 1, 2025, Needham analyst David Saxon maintained a "Buy" rating for Glaukos (GKOS). Despite the reaffirmation of the rating, the firm has adjusted the pri

The headline numbers for Glaukos (GKOS) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

India-based Zoomcar Holdings, Inc. (ZCAR) is up over 123 percent in Thursday's pre-market trading. The following are some of the other stocks making big moves in Thursday's pre-market trading.

Apr 30, 2025 / 08:30PM GMTOperator Welcome to Glaukos Corporation first quarter 2025 financial results conference call. Copies of the company's press release an

Discover key insights from Glaukos Corporation's Q1 2025 earnings call, highlighting iDose TR growth, strong financials, pipeline progress, and 2025...

Glaukos Corporation (NYSE:GKOS) Q1 2025 Earnings Conference Call April 30, 2025 4:30 PM ETCompany ParticipantsChris Lewis - Vice President of Investor...

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal

Baron Health Care Fund retreated in the first quarter of 2025, underperforming its benchmark, the Russell 3000 Health Care Index. Read more here.

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal

Alcon, Glaukos and Regeneron Pharmaceuticals are part of the Zacks top Analyst Blog.

Mizuho Financial Group analysts reveal that the spending power of America's aging population, particularly those aged 75 and above, will significantly impact the market, unlocking a $1 trillion opportunity, termed

Americans over the age of 75 are expected to grow their spending by more than $2 trillion in the next 10 years, according to Mizuho.

GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism.

Topcon Healthcare, Inc., RadiusXR, and Glaukos Corporation (NYSE: GKOS) announced a new collaboration and the launch of RadiusXR's new wearable vision testing

We recently compiled a list of the 7 Best Medical Technology Stocks To Buy According To Analysts. In this article, we are going to take a look at where Glaukos Corporation (NYSE:GKOS) stands against ...